Literature DB >> 31326279

TREX1 variants in Sjogren's syndrome related lymphomagenesis.

Adrianos Nezos1, Panagiota Makri1, Saviana Gandolfo2, Salvatore De Vita2, Michael Voulgarelis3, Mary K Crow4, Clio P Mavragani5.   

Abstract

Genetic variants of the three-prime repair exonuclease 1 (TREX1) -an exonuclease involved in DNA repair and degradation- have been previously found to increase susceptibility to Aicardi Goutieres syndrome, familial chilblain lupus and systemic lupus erythematosus. We aimed to explore whether TREX1 common variants could influence the risk of primary Sjogren's syndrome (SS) and SS-related lymphoma. Three single nucleotide polymorphisms (SNPs) of the TREX1 gene (rs11797, rs3135941 and rs3135945) were evaluated in 229 SS, 89 SS-lymphoma (70 SS-MALT and 19 SS non-MALT) and 240 healthy controls by PCR-based assays. In available 52 peripheral blood and 26 minor salivary gland tissues from our SS cohort, mRNA expression of type I interferon (IFN) related genes and TREX1 was determined by real-time PCR. Significantly decreased prevalence of rs11797 A minor allele was detected in SS patients complicated by non-MALT lymphoma compared to controls (ΟR [95% CI]: 0.4 [0.2-0.9], p-value: 0.02). SS patients carrying the rs11797 AA genotype had increased type I IFN related gene mRNA expression in minor salivary gland tissues. These data support genetically related dampened type I IFN production as an additional mechanism for SS-related lymphomagenesis.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Genetics; Lymphoma; Single nucleotide polymorphisms (SNPs); Sjogren’s syndrome (SS); Three-prime repair exonuclease 1 (TREX1)

Year:  2019        PMID: 31326279     DOI: 10.1016/j.cyto.2019.154781

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

1.  Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of Sjögren's Syndrome Patients.

Authors:  Konstantina D Kourou; Vasileios C Pezoulas; Eleni I Georga; Themis Exarchos; Costas Papaloukas; Michalis Voulgarelis; Andreas Goules; Andrianos Nezos; Athanasios G Tzioufas; Earalampos M Moutsopoulos; Clio Mavragani; Dimitrios I Fotiadis
Journal:  IEEE Open J Eng Med Biol       Date:  2020-02-14

2.  Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren's Syndrome.

Authors:  Evangelia Argyriou; Adrianos Nezos; Petros Roussos; Aliki Venetsanopoulou; Michael Voulgarelis; Kyriaki Boki; Athanasios G Tzioufas; Haralampos M Moutsopoulos; Clio P Mavragani
Journal:  J Clin Med       Date:  2021-02-08       Impact factor: 4.241

3.  Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?

Authors:  Adrianos Nezos; Charalampos Skarlis; Anna Psarrou; Konstantinos Markakis; Panagiotis Garantziotis; Asimina Papanikolaou; Fotini Gravani; Michael Voulgarelis; Athanasios G Tzioufas; Michael Koutsilieris; Haralampos M Moutsopoulos; Eleni Kotsifaki; Clio P Mavragani
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

4.  Type I interferon.

Authors:  Timothy B Niewold
Journal:  Cytokine       Date:  2020-04-22       Impact factor: 3.861

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.